Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biocon Ltd. Capital/Financing Update 2026

Jan 21, 2026

61176_rns_2026-01-21_389d79ba-597c-4b09-960e-a7ee78543226.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [131 x 52] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T: 91 80 2808 2808 F: 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com

BIO/SECL/TG/2025-26/164

January 21, 2026

January 21, 2026
To,The SecretaryBSE LimitedDepartment of Corporate ServicesPhiroze Jeejeebhoy Towers,Dalal Street,Mumbai – 400 001 To,The SecretaryNational Stock Exchange of India LimitedCorporate Communication DepartmentExchange Plaza, Bandra Kurla ComplexMumbai – 400 050
Scrip Code – 532523 Scrip Symbol - Biocon

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is further to our intimation dated December 06, 2025, with respect to the outcome of the meeting of the Board of Directors (“ Board ”) held on December 06, 2025, whereby the Board had approved the acquisition of equity shares of Biocon Biologics Limited (‘ BBL ’), an unlisted material subsidiary of the Company held by various Investors, including acquisition of 14,36,69,382 equity shares from Mylan Inc. by way of cash consideration of USD 400 million.

In this regard and in continuation of our intimation dated January 05, 2026 in respect of completion of acquisition of 7,18,34,691 equity shares from Mylan Inc. out of the aforesaid acquisition of 14,36,69,382 equity shares, please be informed that the Company has today i.e. on January 21, 2026 completed the acquisition of balance 7,18,34,691 equity shares of BBL from Mylan Inc. against cash consideration of USD 200 million.

Post the aforesaid acquisition, the Company holds ~98% of the paid-up equity share capital of BBL on a fully diluted basis.

The above-mentioned information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

For Biocon Limited

Digitally signed RAJESH by RAJESH UMAKANT UMAKANT SHANOY SHANOY Date: 2026.01.21 19:53:25 +05'30' ________________

Rajesh U. Shanoy Company Secretary and Compliance officer ICSI Membership Number: A16328